Sort
10,766 grants matching “checkpoint inhibitor”
Integration of stromal targeting agents with immune checkpoint therapy
$337,607Lei Zheng · Johns Hopkins University · P01 · FY2023 · CA
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
$337,377Alonso Heredia · University Of Maryland Baltimore · R01 · FY2020 · CA
Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven breast cancer
$337,356Xi Chen · Baylor College Of Medicine · P50 · FY2022 · CA
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
$337,329Alonso Heredia · University Of Maryland Baltimore · R01 · FY2021 · CA
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
$337,329Alonso Heredia · University Of Maryland Baltimore · R01 · FY2023 · CA
MerTK and the Innate Immune Response to Melanoma
$337,268Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade
$337,216Harriet M Kluger · Yale University · P50 · FY2020 · CA
Expression of Class I Specific Receptors in NK Cells
$337,172David H Raulet · University Of California Berkeley · R01 · FY2006 · AI
Project 2: Targeting RTK Co-Dependencies in Triple-Negative Breast Cancer
$337,055Thomas Westbrook · Baylor College Of Medicine · P50 · FY2022 · CA
A novel approach for the selective inhibition of HIF-2a in kidney cancer
$336,943Mei Yee Koh · University Of Utah · R01 · FY2021 · CA
A novel approach for the selective inhibition of HIF-2a in kidney cancer
$336,943Mei Yee Koh · University Of Utah · R01 · FY2020 · CA
A novel approach for the selective inhibition of HIF-2a in kidney cancer
$336,943Mei Yee Koh · University Of Utah · R01 · FY2018 · CA
Strategies to improve outcomes for TNBC patients that integrate subtype-specific genomic and immune-based discoveries
$336,917Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2023 · CA
Strategies to improve outcomes for TNBC patients that integrate subtype-specific genomic and immune-based discoveries
$336,917Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2022 · CA
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy
$336,889Szu-Wen Wang · University Of California-Irvine · R01 · FY2022 · EB
Genome-wide mapping and characterization of exitrons in human cancer
$336,711Rendong Yang · Northwestern University At Chicago · R01 · FY2024 · CA
Transformation by the NEU Oncogene Product and EGF
$336,647David F Stern · Yale University · R01 · FY2011 · CA
Regulation of PD-L1/PD-1 immune checkpoints by cis-interactions
$336,567Enfu Hui · University Of California, San Diego · R37 · FY2024 · CA
A phase-1 trial of intraperitoneal 5-fluorouracil and oxaliplatin in patients with colorectal cancer and unresectable peritoneal metastasis.
$336,425Arjun Mittra · Ohio State University · R21 · FY2023 · CA
ROLE AND REGULATION OF CDK4 IN THE NORMAL LENS
$336,401Dana-Farber Cancer Institute · R01 · FY2000 · EY
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin Effector
$336,327Xin Lu · University Of Notre Dame · R01 · FY2024 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
$336,288Wendy S. Garrett · Harvard School Of Public Health · R01 · FY2019 · CA
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy
$336,191David G Denardo · Washington University · P50 · FY2020 · CA
Chk1 signaling in the G2 DNA damage checkpoint
$336,042Matthew J O'Connell · Icahn School Of Medicine At Mount Sinai · R56 · FY2009 · CA
A Novel Pathway Involving E2F1, ATM and NBS1
$335,975University Of Texas Md Anderson Can Ctr · R01 · FY2004 · CA